Literature DB >> 11298545

Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial.

I Wang1, N Bendsoe, C A Klinteberg, A M Enejder, S Andersson-Engels, S Svanberg, K Svanberg.   

Abstract

BACKGROUND: A previously reported randomized clinical trial showed treatment of Bowen's disease using photodynamic therapy (PDT) with topically applied delta-aminolaevulinic acid (ALA) to be at least as effective as cryosurgery and to be associated with fewer adverse effects.
OBJECTIVES: To compare ALA-PDT and cryotherapy in the treatment of histopathologically verified basal cell carcinomas (BCCs) in a non-blinded, prospective phase III clinical trial.
METHODS: One lesion from each of 88 patients was included. The BCCs were divided into superficial and nodular lesions. The follow-up period was restricted to 1 year with close follow-up for the first 3 months. Efficacy was assessed as the recurrence rate 12 months after the first treatment session, verified by histopathology. Tolerability was evaluated as the time of healing, pain and discomfort during and after the treatment, and final cosmetic outcome.
RESULTS: Histopathologically verified recurrence rates in the two groups were statistically comparable and were 25% (11 of 44) for ALA-PDT and 15% (six of 39) for cryosurgery. However, clinical recurrence rates were only 5% (two of 44) for PDT and 13% (five of 39) for cryosurgery. Additional treatments, usually one, had to be performed in 30% of the lesions in the PDT group. The healing time was considerably shorter and the cosmetic outcome significantly better with PDT. Pain and discomfort during the treatment session and in the following week were low, and were equivalent with the two treatment modalities.
CONCLUSIONS: In terms of efficacy, ALA-PDT is comparable with cryosurgery as a treatment modality for BCCs. Retreatments are more often required with PDT than with cryosurgery. This can easily be performed due to the shorter healing time, less scarring and better cosmetic outcome that follows ALA-PDT.

Entities:  

Mesh:

Year:  2001        PMID: 11298545     DOI: 10.1046/j.1365-2133.2001.04141.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  43 in total

1.  A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer.

Authors:  Nathalie C Zeitouni; Ulas Sunar; Daniel J Rohrbach; Anne D Paquette; David A Bellnier; Yi Shi; Gregory Wilding; Thomas H Foster; Barbara W Henderson
Journal:  Dermatol Surg       Date:  2014-12       Impact factor: 3.398

Review 2.  [Cryosurgery in dermatology].

Authors:  C C Zouboulis
Journal:  Hautarzt       Date:  2015-11       Impact factor: 0.751

Review 3.  [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].

Authors:  R-M Szeimies; S Karrer; H Bäcker
Journal:  Hautarzt       Date:  2005-05       Impact factor: 0.751

Review 4.  [Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review].

Authors:  A Sidoroff
Journal:  Hautarzt       Date:  2007-07       Impact factor: 0.751

5.  Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses.

Authors:  Allison Marrero; Theresa Becker; Ulas Sunar; Janet Morgan; David Bellnier
Journal:  Photochem Photobiol       Date:  2011-06-13       Impact factor: 3.421

Review 6.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

Review 7.  Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents.

Authors:  Nela Malatesti; Ivana Munitic; Igor Jurak
Journal:  Biophys Rev       Date:  2017-03-24

8.  The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.

Authors:  Mara Ozolins; Hywel C Williams; Sarah J Armstrong; Fiona J Bath-Hextall
Journal:  Trials       Date:  2010-04-21       Impact factor: 2.279

9.  Histopathology and laser autofluorescence of ischemic kidneys of rats.

Authors:  Luís Fernando Tirapelli; Beatriz F M Trazzi; Vanderlei S Bagnato; Daniela P C Tirapelli; Cristina Kurachi; Mardoqueu Martins da Costa; Silvio Tucci; Adauto J Cologna; Antonio C P Martins
Journal:  Lasers Med Sci       Date:  2008-06-26       Impact factor: 3.161

Review 10.  Pain associated with aminolevulinic acid-photodynamic therapy of skin disease.

Authors:  Christine B Warren; Laszlo J Karai; Allison Vidimos; Edward V Maytin
Journal:  J Am Acad Dermatol       Date:  2009-12       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.